Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079943 | 0.88 | PTGER1 (0.41) | MAP4K4MCL1PTGER1PTPN1 | |
| SCHEMBL6080066 | 0.85 | PTGER1 (0.43) | MCL1PTGER1PTPN1PPIA | |
| SCHEMBL6079219 | 0.85 | ERN1 (0.48) | MCL1MRGPRX4DHODHPTGER1 | |
| SCHEMBL6080257 | 0.84 | PTGER1 (0.41) | MAP4K4MCL1MRGPRX4PTGER1 | |
| SCHEMBL6080659 | 0.83 | PTGER1 (0.44) | MCL1MRGPRX4PTGER1 | |
| SCHEMBL6592997 | 0.82 | MCL1 (0.51) | MAP4K4MCL1MRGPRX4DHODHPTGER1 | |
| SCHEMBL6080053 | 0.77 | MMP2 (0.39) | MAP4K4MCL1MRGPRX4PTGER1 | |
| SCHEMBL6079994 | 0.76 | DHODH (0.46) | MAP4K4MCL1MRGPRX4DHODHPTGER1 | |
| SCHEMBL6080645 | 0.75 | P2RY14 (0.43) | MCL1PTGER1NR4A2 | |
| SCHEMBL6081088 | 0.75 | RXRA (0.41) | MCL1MRGPRX4DHODHPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | MAP4K4 708/4885MCL1 998/4885MRGPRX4 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.